[Globe Newswire] Intra-Cellular Therapies Inc (NASDAQ:ITCI)(TREND ANALYSIS) announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2015 Healthcare Conference 2015 in New York, NY. The presentation is scheduled for Tuesday, September 29, 2015 at 11:30 AM EDT.
The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Intra-Cellular Therapies Inc (NASDAQ:ITCI) stock is currently trading 32.04% below its 52-week-high, 208.98% above its 52-week-low. The 1-year stock price history is in the range of $13.37 – $60.79. Intra-Cellular Therapies Inc (ITCI) has a price to book ratio of 8.06. ITCI stock price has outperformed the Nasdaq by 134.1%. The Medical Drugs company is currently valued at $1.45 billion and its share price closed the last trading session at $41.31. The stock has a 50-day moving average of $32.83 and a 200-day moving average of $28.39.
Intra-Cellular Therapies Inc (ITCI) current short interest stands at 2.33 million shares. It has increased by 14% from the same period of last month. Around 11% of the company’s shares, which are float, are short sold. With a 10-days average volume of 4.61 million shares, the number of days required to cover the short positions stand at 0.6 day.
The company is expected to announce next quarter earnings on November 02, at consensus estimate of $-0.7. Intra-Cellular Therapies Inc (ITCI) reported last quarter earnings on August 05. The Medical Drugs company announced earnings per share of $-0.61 against a consensus Street estimate of $-0.74, beating the average estimate by $0.13. This corresponds to a decrease of $0.59 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently seven analysts that cover Intra-Cellular Therapies Inc stock. Of those seven, seven have a Buy rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $75.
A recent analyst activity consisted of RBC Capital reiterating their Outperform stance on September 17. RBC Capital increased their price target on ITCI from $42 to $62. This corresponds to a 50.08% upside from the last closing price. On the date of report, the stock closed at $58.62.
SunTrust Robinson Humphrey initiated their coverage on the stock with Buy rating on May 6, and fixed their price target at $50. This corresponds to a 21.04% upside from the last closing price. On the date of report, the stock closed at $21.37.
Intra-Cellular Therapies Inc (ITCI) has no debt. The Major Drug Manufacturing sector debt to equity ratio average stands at 62.2%. The company has a current ratio of 22.82. This ratio should be higher than one (ideally two) and is an indicator to show if the company is able to finance its short term obligations. Indeed it should have higher short term assets to dispose in order to cover for its short term liabilities.
Intra-Cellular Therapies Inc. researches and develops biopharmaceutical drugs. The Company engages in the research and development of small molecule drugs to treat neuropsychiatric and neurological diseases and other disorders of the central nervous system. Intra-Cellular Therapies offers its products to the medical industry.